Page 92 - Read Online

Page 456 Michaelis et al. Cancer Drug Resist 2019;2:447-56 I http://dx.doi.org/10.20517/cdr.2019.005

98. Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2
inhibitor enasidenib. Nat Med 2018;24:1167-77.
99. Schulte M, Köster J, Rahmann S, Schramm A. Cancer evolution, mutations, and clonal selection in relapse neuroblastoma. Cell Tissue
Res 2018;372:263-8.
100. Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance
to estrogen receptor-directed therapies. Nat Genet 2019;51:207-16.
101. Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, et al. EGFR and MET Amplifications Determine Response to HER2 Inhibition
in ERBB2-Amplified Esophagogastric Cancer. Cancer Discov 2019;9:199-209.
102. Michaelis M, Schneider C, Rothweiler F, Rothenburger T, Mernberger M, et al. TP53 mutations and drug sensitivity in acute myeloid
leukaemia cells with acquired MDM2 inhibitor resistance. biorXiv 2018, doi: 10.1101/404475.
103. Su Y, Wei W, Robert L, Xue M, Tsoi J, et al. Single-cell analysis resolves the cell state transition and signaling dynamics associated with
melanoma drug-induced resistance. Proc Natl Acad Sci U S A 2017;114:13679-84.
104. Sharma A, Cao EY, Kumar V, Zhang X, Leong HS, et al. Longitudinal single-cell RNA sequencing of patient-derived primary cells
reveals drug-induced infidelity in stem cell hierarchy. Nat Commun 2018;9:4931.
105. Behrens D, Walther W, Fichtner I. Pancreatic cancer models for translational research. Pharmacol Ther 2017;173:146-58.
106. Fichtner I, Klinghammer K, Behrens D, Flechsig S, Rolff J, et al. Animal models for personalized treatment options. Int J Clin Pharmacol
Ther 2017;55:698-700.
107. Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, et al. Primary Patient-Derived Cancer Cells and Their Potential for Personalized
Cancer Patient Care. Cell Rep 2017;21:3298-309.
108. Lampreht Tratar U, Horvat S, Cemazar M. Transgenic Mouse Models in Cancer Research. Front Oncol 2018;8:268.
109. Tellez-Gabriel M, Cochonneau D, Cadé M, Jubellin C, Heymann MF, et al. Circulating Tumor Cell-Derived Pre-Clinical Models for
Personalized Medicine. Cancers (Basel) 2018;11. pii: E19.
110. Xu H, Lyu X, Yi M, Zhao W, Song Y, et al. Organoid technology and applications in cancer research. J Hematol Oncol 2018;11:116.
111. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid
Tumors. Cells 2019;8. pii: E418.
112. Ramamoorthy P, Thomas SM, Kaushik G, Subramaniam D, Chastain KM, et al. Metastatic Tumor-in-a-Dish, a Novel Multicellular
Organoid to Study Lung Colonization and Predict Therapeutic Response. Cancer Res 2019;79:1681-95.
113. Smith RC, Tabar V. Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids. Cell Stem Cell
2019;24:12-24.
114. Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer 2019;19:65-81.
115. Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, et al. Development and characterization of a tamoxifen-resistant breast
carcinoma xenograft. Br J Cancer 2000;82:1844-50.
116. Zhang Z, Lee JC, Lin L, Olivas V, Au V, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nat Genet 2012;44:852-60.
117. Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, et al. Acquired resistance to endocrine treatments is associated with tumor-
specific molecular changes in patient-derived luminal breast cancer xenografts. Clin Cancer Res 2014;20:4314-25.
118. Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, et al. Sequential Salinomycin Treatment Results in Resistance Formation
through Clonal Selection of Epithelial-Like Tumor Cells. Transl Oncol 2014;7:702-11.
119. Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus
cetuximab is associated with activation of mTORC1. Cell Rep 2014;7:999-1008.
120. Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-
ALK-Positive Human Non-Small Cell Lung Cancer. J Thorac Oncol 2017;12:491-500.
121. Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, et al. An approach to suppress the evolution of resistance in BRAFV600E-mutant
cancer. Nat Med 2017;23:929-37.
122. Buzzelli JN, Ouaret D, Brown G, Allen PD, Muschel RJ. Colorectal cancer liver metastases organoids retain characteristics of original
tumor and acquire chemotherapy resistance. Stem Cell Res 2018;27:109-20.
123. Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, et al. The BET bromodomain inhibitor CPI203
overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double
hit lymphoma. Oncogene 2018;37:1830-44.
124. Lau WM, Teng E, Huang KK, Tan JW, Das K, et al. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an
AKT-Independent PKC-Mediated Phosphorylation of GSK3β. Mol Cancer Ther 2018;17:232-42.
125. Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, et al. Enhancer Remodeling and MicroRNA Alterations Are Associated with
Acquired Resistance to ALK Inhibitors. Cancer Res 2018;78:3350-62.